Stockreport

SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF - Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement -  - Trial to Enroll Patients with Ovarian, Colorectal, Triple Negative [Read more]